<DOC>
	<DOCNO>NCT02246049</DOCNO>
	<brief_summary>The purpose study assess efficacy tolerability combination therapy FOLFOXIRI Bevacizumab ( BV ) first-line therapy patient metastatic colorectal cancer .</brief_summary>
	<brief_title>A Multicenter , Clinical Study FOLFOXIRI With Bevacizumab As First-line Therapy Patients With mCRC</brief_title>
	<detailed_description>This single-arm , multicentre phase II study evaluate efficacy safety Bevacizumab ( BV ) combination oxaliplatin , irinotecan hydrochloride , fluorouracil , leucovorin calcium regimen ( FOLFOXIRI +BV ; Falcone et al . ASCO2013 ) first-line treatment Japanese metastatic colorectal cancer patient . This study compose two step collect safety issue Japanese patient . As First step ( Step 1 ) , It assess initial safety information ten Japanese patient end 2nd cycle . evaluate DMC . In parallel confirmation initial safety issue , register 65 case total Step 1 patient , evaluate efficacy safety ( Step2 ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Written Informed consent . 2 . Histopathologically proven diagnosis colorectal cancer ( adenocarcinoma ) exclude vermiform appendix cancer proctos cancer . 3 . Not resectable metastatic colorectal cancer 4 . Age enrollment &gt; = 20 &lt; = 75 year 5 . ECOG PS &lt; 2 age &lt; 70 year , ECOG PS = 0 age = 7175 year 6 . One measurable lesion RECIST ver.1.1 criterion accord contrast enhance CT chest / abdomen / pelvis diagnosis . 7 . Not previously treat chemotherapy . ( Previous adjuvant fluoropyrimidine monotherapy allow 24 week elapsed end adjuvant therapy first relapse . ) 8 . Vital organ function ( list ) preserve within 2 week prior entry . Data record near entry refer . Blood transfusion erythropoiesis stimulate agent less 2 week prior test allow . Neu . &gt; = 1,500/cubicmillimeter Pt . &gt; = 100,000/cubicmillimeter Hb . &gt; = 9.0 g/dL Tbil . &lt; = upper limit normal ( ULN ) *1.5 AST ALT , ALP &lt; = upper limit normal ( ULN ) *2.5 ( &lt; = ULN*5 case liver metastasis ) Serum creatinine &lt; = upper limit normal ( ULN ) *1.5 PTINR &lt; 1.5 Proteinuria &lt; = 2+ 9 . UGT1A1 genotype test . Categorized Wild single Hetero . 1 . Previously treat irradiation bone marrow constitute 20 % irradiation field . 2 . Untreated brain metastasis spinal cord compression primary brain tumor . 3 . History CNS disease . [ except asymptomatic Lacunar stroke ] 4 . Requiring chronic systemic corticosteroid treatment . 5 . Current recent ongoing treatment anticoagulant . 6 . Clinically significant cardiovascular disease example cerebrovascular accident , myocardial infarction , unstable angina , congestive heart failure , serious cardiac arrhythmia require medication . 7 . Treatment investigational drug within 4 week . 8 . Patient Uncontrolled hypertension , Uncontrolled diabetes , Uncontrolled diarrhea , &gt; =grade 1 peripheral neuropathy , Active peptic ulcer , Nonhealing wound , Clinically important disease . 9 . Major surgical procedure within 28 day prior study treatment start , open biopsy , significant traumatic injury , anticipation need major surgical procedure . [ except implantation central venous catheter port system . ] 10 . Lack physical integrity upper gastrointestinal tract . 11 . Pregnant woman , lactate woman , positive pregnancy test , wish become pregnant , Sexually active male . 12 . Hepatitis B hepatitis C. Evidence HIV infection . 13 . Previous Chemotherapy organ . 14 . Other active coexist malignancy . 15 . History / Presence thrombosis within 1 year require medication . 16 . History / Presence paralytic ileus , obstruction gastrointestinal perforation . 17 . Malignant coelomic fluid require drainage . 18 . History allergy Chinese hamster ovary cell protein , component study medication . 19 . History fluoropyrimidine severe side effect cause DPD defect . 20 . Interstitial pneumonitis pulmonary fibrosis . 21 . Evidence require systemic treatment Infectious disease . 22 . Patient judge investigator inappropriate study participation reason .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Metastatic colorectal cancer , bevacizumab , FOLFOXIRI</keyword>
</DOC>